Start where you are
Someone may be thin with little subcutaneous fat but can still have significant visceral fat, while someone with significant subcutaneous fat may not have as much visceral fat
Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis
At 80 weeks, all doses of retatrutide (4 mg, 9 mg, and 12 mg) met the primary and key secondary endpoints for obesity, delivering clinically meaningful weight loss
The glucagon receptor increases energy expenditure and promotes fat burning
The glucagon peptide family [glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) and glucagon] Figure 2: Simplified schematic overview of the glucagon superfamily of peptides [28] The glucagon peptide family members [GLP-1, GIP and glucagon] have similar peptide sequences, permitting the development of single-sequence multi-receptor agonists [4]